These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 9340558)

  • 1. [European registration of medicines: pros and cons for prescriber and patient].
    Offerhaus L
    Ned Tijdschr Geneeskd; 1997 May; 141(21):1028-33. PubMed ID: 9340558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The European Medicines Agency: an overview of its mission, responsibilities, and recent initiatives in cancer drug regulation.
    Pignatti F; Gravanis I; Herold R; Vamvakas S; Jonsson B; Marty M
    Clin Cancer Res; 2011 Aug; 17(16):5220-5. PubMed ID: 21844037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient-reported outcomes: assessment and current perspectives of the guidelines of the Food and Drug Administration and the reflection paper of the European Medicines Agency.
    Bottomley A; Jones D; Claassens L
    Eur J Cancer; 2009 Feb; 45(3):347-53. PubMed ID: 19013787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medicines for children licensed by the European Agency for the Evaluation of Medicinal Products.
    Ceci A; Felisi M; Catapano M; Baiardi P; Cipollina L; Ravera S; Bagnulo S; Reggio S; Rondini G
    Eur J Clin Pharmacol; 2002 Nov; 58(8):495-500. PubMed ID: 12451425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [New drugs and European procedures of approval. The European Agency for the Evaluation of Medicinal Products' role].
    Ainsworth MA
    Ugeskr Laeger; 2003 Apr; 165(16):1648-9. PubMed ID: 12756819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Registration of new medicinal products in Europe].
    Singer E
    Onkologie; 2008; 31 Suppl 2():64-6. PubMed ID: 18487872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Statisticians in European regulatory agencies.
    Skovlund E
    Pharm Stat; 2009; 8(4):259-63. PubMed ID: 19301357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccinovigilance in Europe--need for timeliness, standardization and resources.
    Lankinen KS; Pastila S; Kilpi T; Nohynek H; Mäkelä PH; Olin P
    Bull World Health Organ; 2004 Nov; 82(11):828-35. PubMed ID: 15640918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Dutch drug registration: greater openness is urgently desired].
    Toenders WG; van Loenhout JW
    Ned Tijdschr Geneeskd; 1997 Oct; 141(43):2051-4. PubMed ID: 9550762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The role of the Danish Medical Products Agency in clinical trials].
    Simonsen AC
    Ugeskr Laeger; 2003 Apr; 165(16):1653-6. PubMed ID: 12756821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Government regulation of pricing and reimbursement of prescription medicines: results of a recent multi-country review.
    Kingham R; Wheeler J
    Food Drug Law J; 2009; 64(1):101-14. PubMed ID: 19998574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Increased commercial financing of national Medical Product Agencies within the EU].
    Ramel B
    Lakartidningen; 2003 Jan; 100(5):338-9. PubMed ID: 12607381
    [No Abstract]   [Full Text] [Related]  

  • 15. [European Agency for the Evaluation of Medicinal Products: five years experience].
    Sauer F
    Bull Mem Acad R Med Belg; 2000; 155(5-6):254-8; discussion 259-62. PubMed ID: 11304960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Availability of comparative trials for the assessment of new medicines in the European Union at the moment of market authorization.
    van Luijn JC; Gribnau FW; Leufkens HG
    Br J Clin Pharmacol; 2007 Feb; 63(2):159-62. PubMed ID: 17166187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Two years with EMEA: towards a unified drug registration within the EEC].
    Lennholm B
    Lakartidningen; 1997 Jan; 94(1-2):8-12. PubMed ID: 9053613
    [No Abstract]   [Full Text] [Related]  

  • 18. Provision of information on regulatory authorities' websites.
    Vitry A; Lexchin J; Sasich L; Dupin-Spriet T; Reed T; Bertele V; Garattini S; Toop L; Hurley E
    Intern Med J; 2008 Jul; 38(7):559-67. PubMed ID: 18336542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The origin of informed consent].
    Mallardi V
    Acta Otorhinolaryngol Ital; 2005 Oct; 25(5):312-27. PubMed ID: 16602332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [European drug policy].
    Sauer F
    Bull Mem Acad R Med Belg; 1993; 148(5-6):207-12; discussion 212-6. PubMed ID: 8142930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.